Capricor Therapeutics Inc.'s Duchenne muscular dystrophy treatment, CAP-1002, received the U.S. Food and Drug Administration's regenerative medicine advanced therapy designation.
The designation will expedite development of the drug, which has also received the FDA's orphan drug and rare pediatric disease designations in the past.
Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness, which could lead to death.
